Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.09.2023 | Case report

Cabozantinib/nivolumab

Fulminant type I diabetes mellitus: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Homma T, et al. Fulminant Type 1 Diabetes Mellitus Caused by Long-Term Nivolumab Administration Followed by Nivolumab plus Cabozantinib Combination. Chemotherapy (Basel) 68 : 44-47, No. 1, Jan 2023. Available from: URL: http://doi.org/10.1159/000527541 Homma T, et al. Fulminant Type 1 Diabetes Mellitus Caused by Long-Term Nivolumab Administration Followed by Nivolumab plus Cabozantinib Combination. Chemotherapy (Basel) 68 : 44-47, No. 1, Jan 2023. Available from: URL: http://​doi.​org/​10.​1159/​000527541
Metadaten
Titel
Cabozantinib/nivolumab
Fulminant type I diabetes mellitus: case report
Publikationsdatum
01.09.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-45491-3

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Tocilizumab

Case report

Patisiran

Case report

Multiple drugs

Case report

Clopidogrel

Case report

Propofol